Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The GRRAND-F trial has been given the green light and is now open to recruitment.

GRRAND-F logo

THE GRRAND-F study has opened to recruitment today (09 January 2020) at the Oxford University Hospital NHS Foundation Trust.

GRRAND-F is a feasibility study to see whether a rehabilitation programme (including physiotherapy sessions, advice for managing pain and coping with fatigue and other common side-effects) is acceptable for patients who have been discharged from hospital following head and neck cancer surgery.

This study will be recruiting 60 participants from 4 NHS sites across England. Following surgery participants will be randomised to receive either standard care including in-patient physiotherapy and an advice leaflet detailing basic exercise and self-care following surgery advice or to also receive up to 6 physiotherapy appoints over a 6 month period.

The study will be investigating the acceptability of the study intervention to patients invited to join the study, study compliance, completion of study paperwork, continuation of the rehabilitation programme at home and the need for further treatment following the initial surgery. A number of participants and physiotherapists delivering the study will also be interviewed to explore any changes required to further improve the programme.

Results from the study will help inform whether a large multi-centre definitive randomised controlled trial should be undertaken.

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.